Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications

LAVAL, Quebec, June 19, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced Arthur J. Shannon has joined the company as senior vice president, head of Investor Relations and Communications.

Mr. Shannon has more than 20 years of experience in the field of investor relations. He joins Valeant from Perrigo, Inc., where he served as vice president of Global Corporate Affairs and European Investor Relations. Prior to that, he held roles of increasing importance in investor relations at Thomson Financial and Dynegy, Inc.

"We're delighted to welcome Art Shannon to the Valeant team," said Paul S. Herendeen, executive vice president, Finance, and chief financial officer, Valeant. "With his in-depth knowledge of the pharmaceutical industry and proven track record in investor relations and strategic communications, Art will quickly become an important conduit between Valeant and the business community."

With the addition of Mr. Shannon, Scott Hirsch will assume the role of senior vice president, chief business strategy officer. Mr. Hirsch will now dedicate his time to key corporate initiatives, including the development and execution of a five-year strategic plan.

Arthur J. Shannon (Biography)

Arthur J. Shannon joined Valeant Pharmaceuticals International, Inc. as senior vice president and head of Investor Relations and Communications on June 19, 2017. He previously held the role of vice president of Global Corporate Affairs and European Investor Relations for 11 years at Perrigo. Prior to that, Mr. Shannon served as vice president of Investor Relations for the Energy/Utility division at Thomson Financial, and earlier in his career, he was a senior director of Investor Relations at Dynegy, Inc. Mr. Shannon has received several accolades throughout his career, including the IR Magazine US Awards' Top IR Professional award in 2012. He holds a Bachelor of Science in Business Administration: Finance from Georgetown University.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements.  These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Investor Contact:
Elif McDonald
[e-mail]
514-856-3855
877-281-6642 (toll free)

Media Contact:
Lainie Keller
[e-mail]
908-927-0917

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-appoints-arthur-j-shannon-as-senior-vice-president-head-of-investor-relations-and-communications-300476211.html

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2017 Canada NewsWire